NCT00516724View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

PHASE1CompletedINTERVENTIONAL

Enrollment

189

Participants

Timeline

Start Date

June 22, 2007

Primary Completion Date

January 4, 2013

Study Completion Date

April 11, 2024

Conditions

Triple Negative Metastatic Breast CancerAdvanced Ovarian CancerCarboplatinPaclitaxel

Interventions

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

DRUG

Carboplatin

intravenous injection

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

Oral

DRUG

Paclitaxel

Intravenous injection

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

Oral

DRUG

Paclitaxel + Carboplatin

Intravenous injection

Trial Locations (4)

1090

Research Site, Brussels

3015

Research Site, Rotterdam

1066 EC

Research Site, Amsterdam

SM2 5NG

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY